Mesenchymal stem cells: current clinical progress in ARDS and COVID-19

Mesenchymal stem cells: current clinical progress in ARDS and COVID-19

Abstract Acute respiratory distress syndrome (ARDS) develops rapidly and has a high mortality rate. Survivors usually have low quality of life. Current clinical management strategies are respiratory support and restricted fluid input, and there is no suggested pharmacological treatment. Mesenchymal...

Full description

Bibliographic Details
Main Authors: Kun Xiao, Fei Hou, Xiuyu Huang, Binbin Li, Zhi Rong Qian, Lixin Xie
Format: Article
Language:English
Published: BMC 2020-07-01
Series:Stem Cell Research & Therapy
Subjects:
Acute respiratory distress syndrome
Cell therapy
Mesenchymal stem cells
COVID-19
Clinical trials
Online Access:http://link.springer.com/article/10.1186/s13287-020-01804-6

Internet

http://link.springer.com/article/10.1186/s13287-020-01804-6

Similar Items